Detalhe da pesquisa
1.
Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial.
Lancet Oncol
; 25(2): 184-197, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38211606
2.
Ipsilateral breast tumor recurrence after breast-conserving surgery: insights into biology and treatment.
Breast Cancer Res Treat
; 202(2): 215-220, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37528263
3.
Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial.
Mol Cancer
; 21(1): 84, 2022 03 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35337339
4.
Natural killer cells in cancer biology and therapy.
Mol Cancer
; 19(1): 120, 2020 08 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32762681
5.
Thermo-immune synergy: Camrelizumab plus microwave ablation in preoperative early-stage breast cancer.
Med
; 5(4): 278-280, 2024 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38614071
6.
CCL19+ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer.
Med
; 4(6): 373-393.e8, 2023 Jun 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37201522
7.
Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer.
Nat Commun
; 14(1): 5112, 2023 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37607916
8.
Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial.
Cell Res
; 33(5): 389-402, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36973538
9.
Comprehensive genomic profiling of breast cancers characterizes germline-somatic mutation interactions mediating therapeutic vulnerabilities.
Cell Discov
; 9(1): 125, 2023 Dec 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38114467
10.
Comprehensive metabolomics expands precision medicine for triple-negative breast cancer.
Cell Res
; 32(5): 477-490, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35105939
11.
Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.
Clin Cancer Res
; 28(13): 2807-2817, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35247906
12.
Triple-negative breast cancer: new treatment strategies in the era of precision medicine.
Sci China Life Sci
; 64(3): 372-388, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32803712
13.
Estrogen receptor-low breast cancer: Biology chaos and treatment paradox.
Cancer Commun (Lond)
; 41(10): 968-980, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34251757
14.
Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response.
J Hematol Oncol
; 14(1): 98, 2021 06 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34172088